In a regulatory filing, Pyxis Oncology (PYXS) disclosed that Pfizer (PFE) bought 1.8M shares of common stock on March 17th in a total transaction size of $5.0M. Shares of Pyxis Oncology are up 26% afterhours at $2.78.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PYXS:
- Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
- Pyxis Oncology announces dosing of first subject in Phase 1 trial of PYX-201
- Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
- Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference